VBL Therapeutics to Present at the Chardan Gene Therapy Conference

TEL AVIV, Israel, Sept. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview via a Fireside Chat format at the Chardan Gene Therapy Conference, being held October 10th at the Westin New York Grand Central hotel in New York City.

Presentation Details:Date:  Tuesday, October 10Time:  1:45pm Eastern Time.Webcast:  http://wsw.com/webcast/chard/vblt/

About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC[email protected] (646) 597-6979

MEDIA CONTACT:Matt Middleman, M.D.LifeSci Public Relations[email protected] (646) 627-8384

You May Also Be Interested In

• Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
• Leeward Capital Corp. Announces Change of Management and Asset Sale and Asset Purchase Transactions